{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:44:44Z","timestamp":1780641884204,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UC Irvine Center for Autism Research & Translation"},{"name":"Thompson Family Foundation for Autism"},{"name":"CDMRP\/U.S. Army","award":["W81XWH-13-1-0144"],"award-info":[{"award-number":["W81XWH-13-1-0144"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neuropharm.2017.08.029","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T03:02:02Z","timestamp":1503543722000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Allosteric modulation of nicotinic and GABA A  receptor subtypes differentially modify autism-like behaviors in the BTBR mouse model"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-3335","authenticated-orcid":false,"given":"Ryan F.","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhtam B.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk J.","family":"Hogenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narielle L.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Dunnigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin W.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2017.08.029_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"8","key":"10.1016\/j.neuropharm.2017.08.029_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrn3956","article-title":"Is birth a critical period in the pathogenesis of autism spectrum disorders?","volume":"16","author":"Ben-Ari","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2017.08.029_bib4","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/npp.2014.138","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression","volume":"39","author":"Brown","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"26","key":"10.1016\/j.neuropharm.2017.08.029_bib5","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1523\/JNEUROSCI.0931-10.2010","article-title":"Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus","volume":"30","author":"Campbell","year":"2010","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.08.029_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10803-008-0646-7","article-title":"GABA(A) receptor downregulation in brains of subjects with autism","volume":"39","author":"Fatemi","year":"2009","journal-title":"J.\u00a0Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.08.029_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2008.08.025","article-title":"The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain","volume":"56","author":"Feuerbach","year":"2009","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2017.08.029_bib8","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1038\/tp.2016.125","article-title":"15q13.3 homozygous knockout mouse model display epilepsy-, autism- and schizophrenia-related phenotypes","volume":"6","author":"Forsingdal","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.08.029_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fnins.2016.00192","article-title":"Neuropathological mechanisms of seizures in autism spectrum disorder","volume":"10","author":"Frye","year":"2016","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.08.029_bib10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1124\/jpet.109.161885","article-title":"Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia","volume":"332","author":"Gee","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.08.029_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0269881117691590","article-title":"First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288","volume":"31","author":"Gee","year":"2017","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.08.029_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5498\/wjp.v6.i1.43","article-title":"Cortical and subcortical gamma amino acid butyric acid deficits in anxiety and stress disorders: clinical implications","volume":"6","author":"Goddard","year":"2016","journal-title":"World J. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.08.029_bib13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2014.01.016","article-title":"Enhancement of inhibitory neurotransmission by GABAA receptors having \u03b12,3-subunits ameliorates behavioral deficits in a mouse model of autism","volume":"81","author":"Han","year":"2014","journal-title":"Neuron"},{"issue":"14","key":"10.1016\/j.neuropharm.2017.08.029_bib14","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1021\/jm070083v","article-title":"Enaminone amides as novel orally active GABAA receptor modulators","volume":"50","author":"Hogenkamp","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"issue":"9\u201310","key":"10.1016\/j.neuropharm.2017.08.029_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00335-014-9514-2","article-title":"The genetic basis of obesity-associated type 2 diabetes (diabesity) in polygenic mouse models","volume":"25","author":"Joost","year":"2014","journal-title":"Mamm. Genome"},{"issue":"13","key":"10.1016\/j.neuropharm.2017.08.029_bib16","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","article-title":"Modulatory effects of \u03b17 nAChRs on the immune system and its relevance for CNS disorders","volume":"73","author":"Kalkman","year":"2016","journal-title":"Cell Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.08.029_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/npp.2013.274","article-title":"Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism","volume":"39","author":"Karvat","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.08.029_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-015-4115-7","article-title":"Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism","volume":"233","author":"Kazdoba","year":"2016","journal-title":"Psychopharmacol. Berl."},{"issue":"4","key":"10.1016\/j.neuropharm.2017.08.029_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pediatrneurol.2012.05.007","article-title":"Sleep in children with autism spectrum disorder","volume":"47","author":"Kotagal","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib20","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/tp.2012.124","article-title":"A\u00a0randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2017.08.029_bib21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10803-006-0123-0","article-title":"Comorbid psychiatric disorders in children with autism: interview development and rates of disorders","volume":"36","author":"Leyfer","year":"2006","journal-title":"J.\u00a0Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib22","series-title":"Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)","author":"Li","year":"2010"},{"issue":"5805","key":"10.1016\/j.neuropharm.2017.08.029_bib23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1126\/science.1134246","article-title":"Sequential interplay of nicotinic and GABAergic signaling guides neuronal development","volume":"314","author":"Liu","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.08.029_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/gim.2014.83","article-title":"Delineating the 15q13.3 microdeletion phenotype: a case series and comprehensive review of the literature","volume":"17","author":"Lowther","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib25","article-title":"Not a single but multiple populations of GABAergic neurons control sleep","author":"Luppi","year":"2016","journal-title":"Sleep. Med. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.08.029_bib26","first-page":"355","article-title":"Paradoxical reactions elicited by diazepam in children with classic autism","volume":"2","author":"Marrosu","year":"1987","journal-title":"Funct. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2017.08.029_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molbrainres.2004.01.003","article-title":"Molecular analysis of nicotinic receptor expression in autism","volume":"123","author":"Martin-Ruiz","year":"2004","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"19","key":"10.1016\/j.neuropharm.2017.08.029_bib29","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.0701321104","article-title":"Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators","volume":"104","author":"Ng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.08.029_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000332884","article-title":"The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome","volume":"33","author":"Olmos-Serrano","year":"2011","journal-title":"Dev. Neurosci."},{"issue":"Pt B","key":"10.1016\/j.neuropharm.2017.08.029_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuropharm.2014.12.028","article-title":"Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states","volume":"96","author":"Picciotto","year":"2015","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2017.08.029_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40263-014-0208-9","article-title":"Targeting the nicotinic cholinergic system to treat attention-deficit\/hyperactivity disorder: rationale and progress to date","volume":"28","author":"Potter","year":"2014","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2017.08.029_bib33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.nbd.2005.01.017","article-title":"Neuronal nicotinic acetylcholine receptor subunits in autism: an immunohistochemical investigation in the thalamus","volume":"19","author":"Ray","year":"2005","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.08.029_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1034\/j.1601-183X.2003.00037.x","article-title":"Model of autism: increased ratio of excitation\/inhibition in key neural systems","volume":"2","author":"Rubenstein","year":"2003","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib35","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1038\/tp.2015.123","article-title":"Shared functional defect in IP\u2083R-mediated calcium signaling in diverse monogenic autism syndromes","volume":"5","author":"Schmunk","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2017.08.029_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/367846","article-title":"Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes","volume":"72","author":"Shao","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.08.029_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/ng.93","article-title":"A\u00a0recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures","volume":"40","author":"Sharp","year":"2008","journal-title":"Nat. Genet."},{"issue":"131","key":"10.1016\/j.neuropharm.2017.08.029_bib38","doi-asserted-by":"crossref","first-page":"131ra51","DOI":"10.1126\/scitranslmed.3003501","article-title":"Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism","volume":"4","author":"Silverman","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.08.029_bib39","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1021\/op3002728","article-title":"A\u00a0robust process for an mGluR5 negative allosteric modulator: difluoromethylation and sonogashira coupling on large scale","volume":"16","author":"Sperry","year":"2012","journal-title":"Org. Process Res. Dev."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2017.08.029_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neubiorev.2014.02.015","article-title":"Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms","volume":"46","author":"Srivastava","year":"2014","journal-title":"Neurosci. Biobehav Rev."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.08.029_bib41","doi-asserted-by":"crossref","first-page":"e27014","DOI":"10.1371\/journal.pone.0027014","article-title":"Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats","volume":"6","author":"Thomsen","year":"2011","journal-title":"PLoS One"},{"issue":"6171","key":"10.1016\/j.neuropharm.2017.08.029_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1247190","article-title":"Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring","volume":"343","author":"Tyzio","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.08.029_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2014.01.072","article-title":"The therapeutic promise of positive allosteric modulation of nicotinic receptors","volume":"727","author":"Uteshev","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.neuropharm.2017.08.029_bib44","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1007\/s00213-015-4058-z","article-title":"Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system","volume":"232","author":"Wang","year":"2015","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.08.029_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuropharm.2014.08.003","article-title":"Altered expression of \u03b4 GABAA receptors in health and disease","volume":"88","author":"Whissell","year":"2015","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2017.08.029_bib46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1523\/JNEUROSCI.4488-13.2014","article-title":"Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders","volume":"34","author":"Xu","year":"2014","journal-title":"J.\u00a0Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.08.029_bib47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0269881113507643","article-title":"Limited central side effects of a \u03b2-subunit subtype-selective GABAA receptor allosteric modulator","volume":"28","author":"Yoshimura","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2017.08.029_bib48","doi-asserted-by":"crossref","first-page":"e82791","DOI":"10.1371\/journal.pone.0082719","article-title":"Nicotine elicits prolonged calcium signaling along ventral hippocampal axons","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T22:48:45Z","timestamp":1529534925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817303969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":47,"alternative-id":["S0028390817303969"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.029","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric modulation of nicotinic and GABAA receptor subtypes differentially modify autism-like behaviors in the BTBR mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}